Pharmaceutical company, Eli Lilly & Co. (NYSE: LLY) edged up on Friday after the company said that fiscal 2013 earnings will beat Street’s estimate despite the fact that two of its key drugs will lose U.S. patent protection during this year.
Continue reading Eli Lilly’s Fiscal 2013 Outlook Betters Street’s Estimate (LLY)